Phaarmasia's ₹18.99 cr land sale flips a ₹1.59 cr loss into a ₹17.57 cr profit
The pharmaceutical company's full-year profit is almost entirely a one-off from an asset sale. Operational revenue grew 94% to ₹47.21 crore, but the land gain is the story.
— 2 earlier stories on Phaarmasia Ltd. →What's new
- Phaarmasia swung to a net profit of ₹17.57 crore from a ₹1.59 crore loss in the prior year.
- An exceptional gain of ₹18.99 crore from a land and building sale drove the turnaround.
- Revenue nearly doubled to ₹47.21 crore, and cash reserves surged from ₹0.36 crore to ₹10.99 crore.
Why this matters
The headline profit is almost entirely a one-off event. Strip out the ₹18.99 crore land gain, and the company's core operations were barely breakeven. The sale provided a massive liquidity boost to a ₹53 crore market-cap firm, but it also masks the underlying profitability story.
What we're watching
- Whether the land sale proceeds are deployed for core operations or sit as cash.
- If revenue growth can sustain without further asset sales to boost the bottom line.
- The company's quarterly operational performance now that the one-off is behind it.
The full read
Phaarmasia's profit is a house built on a one-off. The ₹17.57 crore net profit for FY26 flips a ₹1.59 crore loss, but the ₹18.99 crore gain from selling land and buildings does the heavy lifting. That gain alone is 35% of the company's ₹53 crore market cap. The operational story is real: revenue grew 94% to ₹47.21 crore. But the bottom line was made by the asset sale, not the pharmaceutical business. The cash position jumped from ₹0.36 crore to ₹10.99 crore as a result. The key now is whether management uses that cash to scale the core business or lets the one-off define the year. The land sale was flagged in earlier quarters, so the profit was not a surprise. The real test is next year's P&L without it.
Questions answered
- How much of the profit came from the land sale versus operations?
- The entire ₹18.99 crore exceptional gain from the land sale exceeds the ₹17.57 crore net profit. This means the company's underlying pharmaceutical operations resulted in a small net loss for the year, once the one-off gain is excluded.
- What was the scale of the operational revenue growth?
- Annual revenue climbed 94% year-on-year to ₹47.21 crore. This operational improvement was overshadowed in the financial statements by the one-off asset sale.
- How did the company's cash position change?
- Cash and bank balances surged from ₹0.36 crore to ₹10.99 crore over the fiscal year. The improvement is directly linked to the proceeds from selling land and buildings.
- Is this financial recovery sustainable?
- The sustainability is questionable because the profit is primarily non-operational. The core business showed strong revenue growth but not yet the scale to generate material standalone profit.
Phaarmasia Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on PHRMASI →- 29 May 2026 · 7:32 PM IST Phaarmasia's ₹18.99 cr land sale flips a ₹1.59 cr loss into a ₹17.57 cr profit
- 46d ago Phaarmasia's ₹17.57 cr profit is a one-off land sale
- 46d ago Phaarmasia approves FY26 results. The filing omits the numbers.